HealthWorksAI Unveils the First Healthcare Data Platform Using xAI Technology

HealthWorksAI, an industry-leading Healthcare analytics company, announces the launch of the 2nd generation of their state-of-the-art xAI program. It’s an advanced analytical approach that collects and processes data, generating in-depth market analysis which standard models do not uncover.

Allowing data scientists an efficient way to measure the impact of various plan attributes/factors, xAI provides a better understanding of the correlation between plan features and beneficiary preference. It also provides insights into the influence of multiple verticals at the market level. The models are then combined with the human-computer interface (HCI) features capable of translating models into practical explanations for end users.

We use a combination of Rule-based algorithms, Random Forest, and Artificial Neural Networks to develop our proprietary prediction, classification, and performance metrics,” says Shreya, Data Scientist of HealthWorksAI™. “Advanced analytics & xAI comes to play in the modeling and evaluation phases of data mining. To achieve this, we use LIME and DeepLIFT, as an example, to achieve far superior results.”

The xAI program, released in early 2021, has been a huge success for HealthWorksAI, leading as their most subscribed platform module in its first year. The 2nd generation, which will see releases begin in early Q2, includes multiple platform enhancements as well as new approaches to xAI methodologies.

“We’re excited to announce the expansion of our xAI program for MA Payors,” noted Jereme Ayers, Chief Growth Officer of HealthWorksAI. “One of the defining aspects of our company is the partnership our clients provide. We appreciate their faith and confidence and look forward to delivering even more for them in 2022!”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version